CS
INDV icon

Credit Suisse’s Indivior Pharmaceuticals INDV Stock Holding History

Credit Suisse’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$284M Sell
167,722
-4,117
-2% -$77.3K 0.27% 64
2023
Q4 		$214K Sell
171,839
-1,057
-0.6% -$18.8K ﹤0.01% 2969
2023
Q3 		$308M Sell
172,896
-5,892
-3% -$134K 0.31% 54
2023
Q2 		$326M Buy
+178,788
New +$4.1M 0.32% 54

Other funds holding INDV

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Credit Suisse's INDV Position: Q1 2024 in Review

Credit Suisse reduced its Indivior Pharmaceuticals (INDV) stake by 2.4% in Q1 2024, selling an estimated $77.3K and leaving 167,722 shares worth $284M. The position accounts for 0.27% of the portfolio, ranked #64.

Credit Suisse first reported a position in INDV in Q2 2023 and has held it in 4 quarters since. The position peaked at $326M in Q2 2023. 95 funds tracked by Wall St. Rank hold INDV as of Q1 2024.

  • Credit Suisse held 167,722 shares of Indivior Pharmaceuticals worth $284M as of Q1 2024.
  • Credit Suisse sold 4,117 Indivior Pharmaceuticals shares in Q1 2024, an estimated $77.3K.
  • Indivior Pharmaceuticals made up 0.27% of Credit Suisse's portfolio in Q1 2024, its #64 holding.
  • Credit Suisse first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 4 quarters since.
  • Credit Suisse's Indivior Pharmaceuticals position peaked at $326M in Q2 2023.
  • 95 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.